| Name | Amedisys Home Health |
|---|---|
| Location | 223 E Oak St Ste 2, Arcadia, Florida |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 107522 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 33901, 33903, 33904, 33905, 33907, 33908, 33909, 33912, 33913, 33914, 33916, 33917, 33919, 33920, 33928, 33936, 33946, 33947, 33948, 33950, 33952, 33953, 33954, 33955, 33971, 33973, 33980, 33981, 33982, 33983, 33990, 33993, 34102, 34108, 34109, 34110, 34112, 34113, 34114, 34116, 34119, 34134, 34135, 34142, 34145, 34223, 34224, 34228, 34229, 34231, 34232, 34233, 34234, 34235, 34236, 34237, 34238, 34239, 34240, 34241, 34243, 34251, 34265, 34266, 34267, 34269, 34275, 34285, 34286, 34287, 34288, 34289, 34291, 34292, 34293, 34295 |
| NPI Number | 1346556842 |
| Organization Name | HEALTHCARE CONSULTANTS ALLIANCE, LLC |
| Doing Business As | DIRECT ACCESS AT HOME |
| Address | 223 E Oak St Apt 3, Arcadia, FL 34266 |
| Phone Number | 239-652-0260 |
News Archive
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
For a non-descript box it wields a mighty name and even more impressive possibilities for people with heart disease. Called the AngioDefender, the machine - no bigger than a shoebox - holds much promise in the ability to personalize cardiac care, say researchers at Lawson Health Research Institute, the research arm of St. Joseph's Health Care London.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.
The accumulation of fat in the liver as a result of chronic alcohol consumption could be prevented by consuming resveratrol, according to a new study with mice. The research found that resveratrol reduced the amount of fat produced in the liver of mice fed alcohol and, at the same time, increased the rate at which fat within the liver is broken down.
› Verified 3 days ago
| Quality Rating: |
News Archive
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
For a non-descript box it wields a mighty name and even more impressive possibilities for people with heart disease. Called the AngioDefender, the machine - no bigger than a shoebox - holds much promise in the ability to personalize cardiac care, say researchers at Lawson Health Research Institute, the research arm of St. Joseph's Health Care London.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.
The accumulation of fat in the liver as a result of chronic alcohol consumption could be prevented by consuming resveratrol, according to a new study with mice. The research found that resveratrol reduced the amount of fat produced in the liver of mice fed alcohol and, at the same time, increased the rate at which fat within the liver is broken down.
› Verified 3 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 99.3 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.6 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 87.5 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 80.4 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 77.7 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 94.4 | 96.4 |
News Archive
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
For a non-descript box it wields a mighty name and even more impressive possibilities for people with heart disease. Called the AngioDefender, the machine - no bigger than a shoebox - holds much promise in the ability to personalize cardiac care, say researchers at Lawson Health Research Institute, the research arm of St. Joseph's Health Care London.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.
The accumulation of fat in the liver as a result of chronic alcohol consumption could be prevented by consuming resveratrol, according to a new study with mice. The research found that resveratrol reduced the amount of fat produced in the liver of mice fed alcohol and, at the same time, increased the rate at which fat within the liver is broken down.
› Verified 3 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 86 | 79.6 |
| How often patients got better at getting in and out of bed | 84.9 | 81.1 |
| How often patients got better at bathing | 91.8 | 82.3 |
| How often patients’ breathing improved | 92.4 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 93.5 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 82.1 | 75 |
| How often home health patients had to be admitted to the hospital | 20.8 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 13.3 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 97.5 | 94 |
News Archive
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
For a non-descript box it wields a mighty name and even more impressive possibilities for people with heart disease. Called the AngioDefender, the machine - no bigger than a shoebox - holds much promise in the ability to personalize cardiac care, say researchers at Lawson Health Research Institute, the research arm of St. Joseph's Health Care London.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.
The accumulation of fat in the liver as a result of chronic alcohol consumption could be prevented by consuming resveratrol, according to a new study with mice. The research found that resveratrol reduced the amount of fat produced in the liver of mice fed alcohol and, at the same time, increased the rate at which fat within the liver is broken down.
› Verified 3 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
For a non-descript box it wields a mighty name and even more impressive possibilities for people with heart disease. Called the AngioDefender, the machine - no bigger than a shoebox - holds much promise in the ability to personalize cardiac care, say researchers at Lawson Health Research Institute, the research arm of St. Joseph's Health Care London.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.
The accumulation of fat in the liver as a result of chronic alcohol consumption could be prevented by consuming resveratrol, according to a new study with mice. The research found that resveratrol reduced the amount of fat produced in the liver of mice fed alcohol and, at the same time, increased the rate at which fat within the liver is broken down.
› Verified 3 days ago
The patient survey data of Amedisys Home Health is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 90 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 88 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 81 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 86 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 78 | 78 |
News Archive
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
For a non-descript box it wields a mighty name and even more impressive possibilities for people with heart disease. Called the AngioDefender, the machine - no bigger than a shoebox - holds much promise in the ability to personalize cardiac care, say researchers at Lawson Health Research Institute, the research arm of St. Joseph's Health Care London.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.
The accumulation of fat in the liver as a result of chronic alcohol consumption could be prevented by consuming resveratrol, according to a new study with mice. The research found that resveratrol reduced the amount of fat produced in the liver of mice fed alcohol and, at the same time, increased the rate at which fat within the liver is broken down.
› Verified 3 days ago
Desoto Memorial Home Health Care Agency Location: 1006 North Mills Ave, Arcadia, Florida 34266 Ratings: Phone: (863) 494-8432 | |
Amedisys Home Health Location: 223 E Oak St Ste 2, Arcadia, Florida 34266 Ratings: Phone: (863) 993-1038 |